Quote:

---

If, and this is a MONSTER if, Leronlimab does prove to be a prophylaxis, we are going to need to scale manufacturing considerably.

---

This is an excellent point, although I believe we will likely need to massively scale manufacturing even without a prophylaxis indication.

There is a growing chorus of concern being expressed by some really smart people regarding vaccine development timelines, vaccine viability in general, and reduced immunological endurance (relating to both convalescent immunity as well as immunity from a potential vaccine).

I admit to being somewhat surprised at the company's nonchalant reaction to repeated questions posed in conference calls regarding the incidence of COVID infection by those in active HIV and Cancer trials.

I realize this is incredibly hard for the company to monitor, especially with all of the other balls in the air. But this would be a massively meaningful and profitable indication if proven efficacious.

As just one example, imagine being able to prevent the deaths of healthcare workers attending to COVID patients -- all over the world.